



HORIZON 2020:

INNOVATIVE MEDICINES INITIATIVE

OPPORTUNITIES FOR THE INDUSTRIAL SECTOR



Marta Gómez Quintanilla Spanish Representative Health & IMI marta.gomez[at]cdti.es

http://bit.ly/1bMnmv5


Barcelona, 13 de enero de 2015

ÍNDICE IMI2

Starting point: where is Spain now?

Key changes, new opportunities in IMI2

Some remarks





ÍNDICE IMI2

Starting point: where is Spain now?

Key changes, new opportunities in IMI2

Some remarks





IMI timeline

www.imi.europa.eu/content/overview-imis-calls-how-participate




- Report including results from call 1 to 8
- Signed projects, updated
 5th February 2014

www.cdti.es/index.asp?MP=7&MS=51&MN=4&T R=A&IDR=1&iddocumento=4519












Spain vs Europe: Where is Spain? (€)











Spanish results: Entities




Entidades destacadas	Ac Nº	ctividades Lideradas
CENTRE DE RECERCA EN SALUT INTERNACIONAL DE BARCELONA	2	0
SYNAPSE RESEARCH MANAGEMENT PARTNERS S. L.	3	0
FUNDACION PROGRESO Y SALUD	1	0
INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER	5	0
INSTITUTO CATALA DE CIENCIES CARDIOVASCULARS	1	0
AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS	3	0
FUNDACIO IMIM	1	0
FUNDACIO INSTITUT CATALA DE FARMACOLOGIA	2	0
SERVICIO ANDALUZ DE SALUD	2	0
UNIVERSIDAD CARLOS III DE MADRID	1	0



Entidades destacadas	A	Actividades	
	Nº	Lideradas	
ALMIRALL SA	7	0	
GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL	1	1	
LABORATORIOS DEL DR ESTEVE, S.A.	6	0	

+ Farmaindustria







ÍNDICE IMI2

Starting point: where is Spain now?

 Key changes, new opportunities in IMI2

Some remarks





IMI Consortium & Call Process




Call Preparation

Call Preparation



IMI Consortium & Call Process






Programas de la UE

New opportunities in IMI2:

<u>In kind/cash contribution</u> matched by IMI funding for public beneficiaries










IMI Consortium & Call Process





New opportunities in IMI2: Eligibility to receive funding



IMI

IMI2

- Academic institutions
- Non-profit organizations
- Small & medium-size enterprises
- Non-profit patient organizations
- Non-profit public bodies
- International European interest organizations

- Academic institutions
- Non-profit organizations
- Small & medium-size enterprises
- Mid-sized enterprises (≤ 500 M€)
- Non-profit patient organizations
- Non-profit public bodies
- International European interest organizations










IMI Consortium & Call Process





IMI2 Timeline









Topics 2014 Calls

- 1. Translational approaches to disease modifying therapy of type 1 diabetes mellitus (T1DM)
- 2. Discovery and validation of novel endpoints in dry agerelated macular degeneration and diabetic retinopathy



- 1. Vaccine development Phase I, II, and III
- 2. Manufacturing capability
- 3. Stability of vaccines during transport and storage
- 4. Deployment and compliance of vaccination regimens
- 5. Rapid diagnostic tests





- Linking clinical neuropsychiatry and quantitative neurobiology
- The consistency approach to quality control in vaccine manufacture
- Pertussis vaccination research
- Knowledge Repository to enable patient focused medicine development
- Enabling platform on medicines adaptive pathway to patients (CSA)











Topics 2014 Calls

- 1. Translational approaches to disease modifying therapy of type 1 diabetes mellitus (T1DM)
- 2. Discovery and validation of novel endpoints in dry agerelated macular degeneration and diabetic retinopathy
 - 1. Vaccine development Phase I, II, and III
 - 2. Manufacturing capability
 - 3. Stability of vaccines during transport and storage
 - 4. Deployment and compliance of vaccination regimens
 - 5. Rapid diagnostic tests
 - 1. Remote assessment for disease and relapse (RADAR), topic 1: central nervous system (CNS)
 - 2. Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification
 - Linking clinical neuropsychiatry and quantit
 - The consistency approach to quality control
 - Pertussis vaccination research
 - Knowledge Repository to enable patient focused medicine development
 - Enabling platform on medicines adaptive pathway to patients (CSA)





No Spanish "industrial partners" so far investing...










NEWDRUGS4BADBUGS (ND4BB) Programme



Call 6 Call 9

Call 8 Call 11

Figure 1 – Overall Architecture of the ND4BB Programme

BE = bronchiectasis; CF = cystic fibrosis; R&D = research and development







IMI2: Ebola+ Programme






Figure 1: Proposed structure of the IMI2 Ebola and other filoviral haemorrhagic fevers (Ebola+)





Oportunities for new players

Example: EBOLA CALL ¿only for clinical players?

- 1. Vaccine development Phase I, II, and III
- 2. Manufacturing capability
 - 3. Stability of vaccines during transport and storage
 - 4. Deployment and compliance of vaccination regimens

The project will be rolled out and operationalised during conduct of the large scale phase II and III vaccination trials conducted under Topic 1 of this Call to assess the safety and efficacy of a candidate vaccine. Those trials offer an opportunity to test and validate any new tools and technologies. One option can be to exploit the high penetration of mobile telecommunication and use of mobile apps in West Africa. Proposals that will use mobile communication strategies to increase awareness, acceptance and subject recruitment in the vaccination campaigns or will create specific apps to remind participants of their appointments and keep track of their response or side effects are encouraged. In this type of project it is essential to guarantee privacy of subjects. To that end the operation as such of the telecommunication infrastructure within the study needs to be clearly separated from the scientific work, for example by having different legal entities responsible for the different aspects.





ÍNDICE IMI2

Starting point: where is Spain now?

Key changes, new opportunities in IMI2

Some remarks





Build your network



www.healthcompetence.eu




www.fitforhealth.eu





www.imi.europa.eu/content/partner-search



www.imi-partnering.eu







Contribute: Strategic Research Agenda



- General context
- Living document







IMI2 –**EFPIA** Idea generation website

http://imi.efpia.eu/imi2/imi2-idea-generation

imi.efpia.eu/imi2/imi2-idea-generation

Innovative Medicines Initiative





Home / IMI2 / IMI2 idea generation

IMI2 idea generation

Create your IMI2
IMI2 idea generation







Participate as an expert

http://ec.europa.eu/research/participants/portal/desktop/en/experts/index.html











Be part of IMI2!



- Stakeholders event (at least one per year)
- Infodays (at international and national level)
- Open consultations
- Evaluate (experts)
- Webinares
- Websites
- IMI office
- NCPs

• ...

Active participation! Solve your doubts! Build your Network!
















NCP = facilitator

http://ec.europa.eu/research/participants/portal/desktop/en/support/national_contact_points.html



NCPs SALUD

Carolina Carrasco (CDTI) - carolina.carrasco@cdti.es Juan Riese (ISCIII) - jriese@isciii.es







CDTI: support ► **NCPs**

Support offices: local/regiona/institutional **IDEA** • National Technological Platforms: MedInn ES... **ENCAJE** Other support services: partners, IPRs, etc. **REVISAR CONSORCIO** PREPARAR PROPUESTA **NEGOCIACION EVALUACION PROYECTO ENVIAR**

OTHERS AVAILABLE TOO!







More information





http://ec.europa.eu/research/horizon2020/index_en.cfm





@EsHorizonte2020



http://eshorizonte2020.cdti.es/index.asp?MP=87&MS=715&MN=2&TR=A&IDR=862&IDP=679&IDS=2



www.eshorizonte2020.es





www.imi.europa.eu/content/subscribe-imi-newsletter







Last remarks



Be ready

- Define a strategy
- Build your network
- Know the rules



Be active

- Participate in events ACTIVELY (local or remotely)
- Contribute to consultations / documents



Get support

- Support offices in your entity
- IMI Representative, NCPs, IMI Office, Industrial Associations...







Final remark

Opportunity rarely knocks on your door. Knock rather on opportunity's door if you ardently wish to enter.

B. C. Forbes



Bertie Charles Forbes (May 14, 1880 – May 6, 1954) was a Scottish financial journalist and author who founded Forbes Magazine.









CONTACT DETAILS:

Marta Gómez Quintanilla
Spanish Representative - HEALTH
Spanish Representative - IMI
Spanish MB Member - JPND

34 91 581 55 62 / 00

marta.gomez[at]cdti.es - www.cdti.es





